Vials of ketamine on a blue background contrasted by a woman getting TMS therapy.

TMS therapy vs. ketamine: which is right for you?

When antidepressants haven’t provided the relief you hoped for, exploring another treatment can feel like starting over.

You may have heard about transcranial magnetic stimulation (TMS) therapy or ketamine treatment, but understanding which approach fits your needs isn’t always straightforward.

Both TMS therapy and ketamine-based treatments may help people with depression that hasn’t responded to medication.

Ketamine can provide faster symptom relief, while TMS therapy offers a non-invasive approach without medication-related sedation. The better choice depends on your symptoms, treatment history, safety considerations, and personal preferences.

For individuals comparing ketamine and TMS therapy in Manhattan, understanding these differences can help make the next decision more informed.

At Neurotherapeutix, we also explore how computational brain mapping may help guide TMS treatment planning.

TMS therapy vs. ketamine at a glance

Note: Treatment outcomes vary based on the individual, protocol, and clinical circumstances. Results from separate studies should not be interpreted as a direct comparison of effectiveness.

Which approach may be right for you?

Ketamine may be appealing when rapid symptom relief is a priority. Accelerated fMRI-guided TMS therapy offers a non-invasive, medication-free alternative that may provide sustained improvement without frequent maintenance visits. The best option depends on your symptoms, treatment history, and individual needs.

What is TMS therapy?

Transcranial magnetic stimulation is a non-invasive treatment that uses controlled magnetic pulses to influence activity in brain regions associated with mood regulation.

During a session, clinicians position an electromagnetic coil against the scalp. Magnetic pulses stimulate neural circuits without requiring surgery or anesthesia.

TMS therapy has been used to treat depression for many years and is FDA-cleared for major depressive disorder using specific devices and protocols.

According to the National Institute of Mental Health (NIMH), conventional TMS treatment often involves sessions five days per week over several weeks, although newer accelerated protocols may use different schedules.

Patients remain awake during treatment and can generally return to their usual activities afterward.

How fMRI-guided TMS therapy differs from standard TMS therapy

Standard TMS therapy typically uses established anatomical landmarks or measurement-based methods to determine stimulation locations.

At Neurotherapeutix, fMRI-guided TMS therapy incorporates resting-state functional MRI and patented computational brain mapping to examine individual brain connectivity patterns.

This information supports personalized stimulation targeting rather than relying solely on standardized anatomical locations.

Understanding personalized vs. standard TMS therapy can help patients explore the potential value of individualized targeting.

Connectivity-guided targeting is an important advancement in personalized TMS therapy, allowing clinicians to use individual brain network patterns to plan treatment more precisely.

What is ketamine treatment for depression?

Ketamine is a medication originally developed for anesthesia.

Researchers later discovered that it can produce rapid antidepressant effects in some individuals, particularly those experiencing depression that has not responded adequately to conventional treatment.

Unlike traditional antidepressants, which primarily affect serotonin, norepinephrine, or related systems, ketamine acts on glutamate-related signaling pathways involved in communication between nerve cells.

The NIMH has highlighted ongoing research into ketamine’s rapid antidepressant effects and the biological mechanisms behind them.

When comparing ketamine and TMS for treatment-resistant depression, it is important to distinguish between IV ketamine and esketamine nasal spray.

IV ketamine infusions

IV ketamine is administered through an intravenous infusion under medical supervision.

Although ketamine is FDA-approved for certain anesthetic uses, IV ketamine is not FDA-approved specifically for treating depression. Its use for depression is considered off-label.

Some patients experience improvements in depressive symptoms within hours or days. However, the effects of a single infusion may be temporary, and clinics often recommend a series of treatments or maintenance visits.

During and after treatment, patients require monitoring because ketamine can cause sedation, dissociation, changes in blood pressure, and other side effects.

Esketamine (Spravato) nasal spray

Spravato contains esketamine, a medication related to ketamine that is administered as a nasal spray.

Unlike IV ketamine for depression, Spravato is FDA-approved for treatment-resistant depression in adults.

Under its updated FDA prescribing information, Spravato may be used alone or alongside an oral antidepressant for treatment-resistant depression.

It must be administered under medical supervision in a certified healthcare setting, with at least two hours of post-dose monitoring.

Patients cannot drive until the following day after a restful sleep.

These requirements make Spravato an established medication-based option, but one that requires substantial scheduling and monitoring.

How do fMRI-guided TMS therapy and ketamine compare?

Although fMRI-guided TMS therapy and ketamine have not been extensively compared in head-to-head clinical trials, each offers potential benefits for treatment-resistant depression.

Understanding their differences in treatment experience, speed of relief, and ongoing care can help patients make more informed decisions.

Side effects and safety

TMS therapy is generally well tolerated and does not involve administering a psychoactive medication.

Common side effects include temporary scalp discomfort, headache, or lightheadedness. Seizures are a rare but serious potential complication, making appropriate screening essential.

Ketamine-based treatments have different safety considerations.

Patients may experience dizziness, nausea, dissociation, sedation, and temporary increases in blood pressure.

Spravato also carries important warnings concerning respiratory depression, misuse, and other serious risks, requiring supervised administration and monitoring.

Neither treatment is suitable for everyone. A clinician should review medical history, psychiatric diagnoses, medications, and relevant risk factors before making a recommendation.

Time commitment

Conventional TMS therapy usually requires frequent outpatient appointments over several weeks. However, Neurotherapeutix accelerated fMRI-guided TMS can be applied on a much shorter time scale and, depending on patients’ constraints, within a few days.

Although the schedule involves repeated visits, treatment generally does not require recovery time afterward.

Ketamine treatment may involve fewer initial appointments, depending on the protocol, but each visit can require additional time for administration, observation, and recovery.

Spravato appointments include at least two hours of monitoring after administration, and patients must arrange transportation rather than drive themselves home.

Maintenance treatment may also extend the overall commitment.

Cost and access

The cost of either treatment depends on the provider, treatment protocol, number of sessions, and insurance benefits.

TMS therapy for eligible depression diagnoses may be covered by some insurance plans, subject to medical necessity requirements and individual policy terms.

Spravato may also be covered for qualifying patients, although prior authorization, certified treatment settings, and monitoring costs can affect access.

IV ketamine for depression is often self-pay because its psychiatric use is off-label.

When comparing costs, patients should consider the full treatment course, including consultations, monitoring, transportation, and potential maintenance sessions.

For additional context, explore our guide to TMS therapy and insurance.

Neurotherapeutix operates as a self-pay clinic and can provide documentation for patients exploring potential out-of-network reimbursement.

Who may be a better candidate for each?

The right treatment depends on your depression history, symptom severity, medical needs, and treatment preferences.

TMS therapy may be worth exploring if you:

  • Have experienced limited improvement with antidepressant medication
  • Prefer a non-invasive, non-medication-based treatment
  • Want to avoid sedation or post-treatment driving restrictions
  • Can attend regular outpatient sessions
  • Are interested in individualized brain connectivity assessment

Ketamine-based treatment may be worth discussing if you:

  • Have treatment-resistant depression and are considering a medication-based alternative
  • Need to explore treatments with a potentially faster onset of action
  • Can accommodate supervised administration and recovery time
  • Have no medical or psychiatric contraindications that would make treatment unsuitable
  • Are comfortable discussing maintenance treatment and medication-related risks

For individuals experiencing severe depression with urgent safety concerns, the priority is immediate psychiatric assessment rather than choosing a routine outpatient treatment based solely on convenience.

Other options may also be relevant. Our comparison of ECT vs. fMRI-guided TMS therapy explains another established approach for difficult-to-treat depression.

You can also review the signs you may be a good candidate for TMS therapy before scheduling an evaluation.

Can you combine or switch between TMS therapy and ketamine?

Yes, some patients may receive TMS therapy after ketamine treatment, or vice versa, depending on their clinical circumstances.

A previous lack of response to one treatment does not automatically mean another approach will be ineffective.

Researchers are also investigating combined treatment strategies, although evidence is still developing and no single combination protocol is established for all patients.

Any decision to combine, transition between, or discontinue treatments should be coordinated by qualified clinicians who can assess safety, timing, and potential interactions.

Why precision targeting matters for long-term results

Depression does not affect every person’s brain in the same way.

Researchers have identified differences in functional connectivity across brain networks involved in mood, motivation, attention, and emotional regulation.

These differences have encouraged interest in more individualized approaches to TMS targeting.

At Neurotherapeutix, patented computational brain mapping examines functional connectivity using resting-state fMRI.

Rather than relying exclusively on standardized anatomical locations, our approach uses individual connectivity patterns to inform where stimulation may be delivered.

Research into connectivity-guided TMS, including accelerated treatment approaches, continues to explore whether more individualized targeting can improve depression outcomes.

For patients interested in a non-invasive treatment designed around their brain network patterns, fMRI-guided TMS therapy offers a personalized approach worth discussing.

Frequently asked questions

Is TMS therapy or ketamine better for treatment-resistant depression?

Both treatments may help appropriately selected patients with treatment-resistant depression.

Ketamine-based treatments offer the possibility of faster symptom relief, while TMS therapy provides a non-invasive approach without medication-related sedation.

The best choice depends on your treatment history, symptoms, medical considerations, and preferences. Current evidence does not establish one as universally superior.

Which works faster, TMS therapy or ketamine?

Ketamine generally has a faster initial onset of antidepressant effects, sometimes within hours or days.

Conventional TMS therapy typically requires multiple sessions before meaningful improvement develops. Accelerated TMS protocols may shorten that timeline, although availability and suitability vary.

Do the results of ketamine last as long as TMS therapy?

The duration of improvement varies with both treatments.

Some patients maintain benefits after completing a TMS course, while others require additional sessions.

Ketamine-based treatment may also provide sustained improvement, particularly with appropriate maintenance care, but benefits can diminish after treatment stops.

There is no reliable way to predict an individual’s long-term response based on treatment type alone.

Can I try TMS therapy if ketamine didn’t work for me?

Yes, TMS therapy may still be an option if ketamine treatment has not provided sufficient relief.

The two treatments work through different mechanisms, and lack of response to one does not automatically rule out benefit from the other.

A comprehensive evaluation can help determine whether TMS therapy is appropriate based on your diagnosis, previous treatments, and medical history.

Does Neurotherapeutix offer ketamine treatment?

Neurotherapeutix specializes in personalized, fMRI-guided TMS therapy rather than ketamine treatment.

Our team can evaluate whether our brain-mapping-guided approach may be appropriate for individuals experiencing persistent depression.

Patients interested in ketamine or Spravato should discuss those options with a qualified prescribing clinician or certified treatment provider.

Find the right next step in Manhattan

When depression persists despite medication, understanding your options can help you move forward with greater confidence.

TMS therapy and ketamine-based treatments offer different approaches, each with potential benefits and important considerations.

At Neurotherapeutix, we combine advanced functional imaging, patented computational brain mapping, and individualized clinical evaluation to explore personalized treatment options for depression.

Neurotherapeutix is the only clinic in the U.S. offering its patented fMRI-guided TMS therapy approach for mental health conditions.

Our Manhattan team can help you determine whether personalized TMS therapy may be appropriate for your needs.

Request an appointment to learn more and get started.

Would You Like to See a Specialist?

Call us at (917) 388-3090 or click to request a regular or telehealth appointment.

Patient Testimonials

11 Total Reviews

Our Location

Neurotherapeutix
171 East 74th Street, Unit 1-1 New York, NY 10021

QUICK INQUIRY

Are you Looking For
More Information?

Contact us to get an estimate for your medical services requirements. You can fill in the form to specify your medical requirements or you can call us directly.

Contact Form

This field is for validation purposes and should be left unchanged.

Request an Appointment